Video: Developing New Treatments for T Cell Lymphoma

Runtime

05:00

Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.

Speaker(s)

Steven M. Horwitz, MD

Steven M. Horwitz - Physician Profile

Related Topics

Lymphoma - Clinical Research Program

See Videos Related to:

For Healthcare Professionals›Lymphoma

brentuximab vedotin (bren-TUK-sih-mab veh-DOH-tin)

A drug used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma that did not get better with other treatment. It is also being studied in the treatment of other types of lymphoma. Brentuximab vedotin is made by combining a monoclonal antibody with an anticancer drug. It binds to a protein called CD30, which is on the surface of some lymphoma cells, and may kill cancer cells. Brentuximab vedotin is a type of antibody-drug conjugate. Also called Adcetris and SGN-35.

Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)

cell (sel)

The individual unit that makes up the tissues of the body. All living things are made up of one or more cells.

Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)

M

In chemistry, M is the amount of a substance that has 6.023 x 10(23) atoms or molecules of that substance. Also called mole (chemical).

Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)

medical oncologist (MEH-dih-kul on-KAH-loh-jist)

A doctor who specializes in diagnosing and treating cancer using chemotherapy, hormonal therapy, biological therapy, and targeted therapy. A medical oncologist often is the main health care provider for someone who has cancer. A medical oncologist also gives supportive care and may coordinate treatment given by other specialists.

Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)

pralatrexate (PRA-luh-TREK-sayt)

A drug used in the treatment of peripheral T-cell lymphoma (a fast-growing form of non-Hodgkin lymphoma). It is also being studied in the treatment of other types of cancer. Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor. Also called FOLOTYN.

Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)

romidepsin (ROH-mih-DEP-sin)

A substance being studied in the treatment of cancer. Romidepsin is a type of depsipeptide and histone deacetylase inhibitor. Also called FR901228.

Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)